Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Zacks News
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
by Zacks Equity Research
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Q3 Earnings Beats: C, GS, BAC, JNJ, WBA; Empire State Lower
by Mark Vickery
While Goldman Sachs (GS) and Citi (C) both impressed on earnings this morning, Walgreens (WBA) looks to bounce back.
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 9.01% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Q3 Earnings Results of U.S. Corporate Giants in Focus
by Zacks Equity Research
Q3 Earnings Results of U.S. Corporate Giants in Focus.
Bank Holiday Ahead of Busy Stock Trading Week
by Mark Vickery
Despite today's day off from econ metrics, we see a pretty busy week ahead.
Johnson & Johnson (JNJ) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.51, denoting a -0.09% change from the preceding trading day.
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?
by Zacks Equity Research
ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month. Let's see if the trend might change.
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Should Investors Consider High Yield Dividend Stocks?
by Derek Lewis
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But is high yield always the way to go?
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.
Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus
by Zacks Equity Research
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today
by Zacks Equity Research
Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $162.78 in the latest trading session, marking a -0.27% move from the prior day.
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
by Kinjel Shah
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
by Zacks Equity Research
The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.